ANIP
Price
$79.15
Change
+$1.43 (+1.84%)
Updated
Jul 21 closing price
Capitalization
1.8B
21 days until earnings call
Intraday BUY SELL Signals
PCRX
Price
$25.78
Change
+$0.43 (+1.70%)
Updated
Jul 21 closing price
Capitalization
1.01B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANIP vs PCRX

ANIP vs PCRX Comparison Chart in %
View a ticker or compare two or three
VS
ANIP vs. PCRX commentary
Jul 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIP is a Hold and PCRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2026
Stock price -- (ANIP: $79.15 vs. PCRX: $25.78)
Brand notoriety: ANIP and PCRX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIP: 37% vs. PCRX: 54%
Market capitalization -- ANIP: $1.8B vs. PCRX: $1.01B
ANIP [@Pharmaceuticals: Generic] is valued at $1.8B. PCRX’s [@Pharmaceuticals: Generic] market capitalization is $1.01B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIP’s FA Score shows that 0 FA rating(s) are green whilePCRX’s FA Score has 1 green FA rating(s).

  • ANIP’s FA Score: 0 green, 5 red.
  • PCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, PCRX is a better buy in the long-term than ANIP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIP’s TA Score shows that 3 TA indicator(s) are bullish while PCRX’s TA Score has 3 bullish TA indicator(s).

  • ANIP’s TA Score: 3 bullish, 6 bearish.
  • PCRX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both ANIP and PCRX are a bad buy in the short-term.

Price Growth

ANIP (@Pharmaceuticals: Generic) experienced а -1.74% price change this week, while PCRX (@Pharmaceuticals: Generic) price change was +3.08% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +14.56%. For the same industry, the average monthly price growth was +11.12%, and the average quarterly price growth was +19.65%.

Reported Earning Dates

ANIP is expected to report earnings on Aug 12, 2026.

PCRX is expected to report earnings on Aug 04, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+14.56% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANIP($1.8B) has a higher market cap than PCRX($1.01B). PCRX has higher P/E ratio than ANIP: PCRX (198.15) vs ANIP (20.24). ANIP YTD gains are higher at: 0.266 vs. PCRX (-0.386). ANIP has higher annual earnings (EBITDA): 224M vs. PCRX (118M). ANIP has more cash in the bank: 326M vs. PCRX (202M). PCRX has less debt than ANIP: PCRX (411M) vs ANIP (614M). ANIP has higher revenues than PCRX: ANIP (924M) vs PCRX (735M).
ANIPPCRXANIP / PCRX
Capitalization1.8B1.01B177%
EBITDA224M118M190%
Gain YTD0.266-0.386-69%
P/E Ratio20.24198.1510%
Revenue924M735M126%
Total Cash326M202M161%
Total Debt614M411M149%
FUNDAMENTALS RATINGS
ANIP vs PCRX: Fundamental Ratings
ANIP
PCRX
OUTLOOK RATING
1..100
7032
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
38100
SMR RATING
1..100
5191
PRICE GROWTH RATING
1..100
5743
P/E GROWTH RATING
1..100
973
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCRX's Valuation (77) in the Pharmaceuticals Other industry is in the same range as ANIP (91). This means that PCRX’s stock grew similarly to ANIP’s over the last 12 months.

ANIP's Profit vs Risk Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for PCRX (100). This means that ANIP’s stock grew somewhat faster than PCRX’s over the last 12 months.

ANIP's SMR Rating (51) in the Pharmaceuticals Other industry is somewhat better than the same rating for PCRX (91). This means that ANIP’s stock grew somewhat faster than PCRX’s over the last 12 months.

PCRX's Price Growth Rating (43) in the Pharmaceuticals Other industry is in the same range as ANIP (57). This means that PCRX’s stock grew similarly to ANIP’s over the last 12 months.

PCRX's P/E Growth Rating (3) in the Pharmaceuticals Other industry is significantly better than the same rating for ANIP (97). This means that PCRX’s stock grew significantly faster than ANIP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIPPCRX
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 7 days ago
73%
Bullish Trend 6 days ago
70%
Declines
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 13 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ANIP
Daily Signal:
Gain/Loss:
PCRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEPGX62.331.00
+1.63%
American Funds EUPAC A
BISRX26.730.09
+0.34%
Brandes International Small Cap EquityR6
CMJAX50.69N/A
N/A
Calvert US Mid Cap Core Rspnb Idx A
ENHCX11.16N/A
N/A
Cullen Enhanced Equity Income C
GOGFX47.12N/A
N/A
Victory Sycamore Small Company Opp R

ANIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIP has been loosely correlated with AMPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIP jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIP
1D Price
Change %
ANIP100%
+1.84%
AMPH - ANIP
41%
Loosely correlated
-0.20%
COLL - ANIP
40%
Loosely correlated
+0.87%
AMRX - ANIP
36%
Loosely correlated
+3.43%
SNDL - ANIP
31%
Poorly correlated
+0.78%
XERS - ANIP
29%
Poorly correlated
+2.09%
More

PCRX and

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
+1.70%
ELAN - PCRX
32%
Poorly correlated
+1.35%
XERS - PCRX
29%
Poorly correlated
+2.09%
ANIP - PCRX
27%
Poorly correlated
+1.84%
SXTC - PCRX
27%
Poorly correlated
+10.29%
ACET - PCRX
27%
Poorly correlated
+2.92%
More